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Objective: The tumor necrosis factor (TNF) and the cellular NF-κB pathway protein IKKβ play important roles in
various cellular processes such as cell proliferation, survival, differentiation, and apoptosis. A heat shock protein 90
inhibitor, 17-DMAG, can induce apoptosis of some tumor cells. This study is to determine the combined effects of
17-DMAG and TNF on malignant cells and the related mechanisms.
Methods: We have determined effects of 17-DMAG, an Hsp90 inhibitor, and TNF treatments on the small cell lung
cancer cell line (MS-1), the adenocarcinoma cell line (A549), the squamous-cell carcinoma cell line (LK-2), and the
normal human bronchial epithelium cell line (NuLi-1) by using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrozolium bromide assay. To determine if 17-DMAG inhibit the expression of IKKβ in the normal human
NuLi-1 cells, and the malignant MS-1, A549, and LK-2 cells, immunoblotting assays and luciferase assays were
performed.
Results: It was found that the combined treatments resulted in synergistic killing of malignant cells, which was
confirmed by the apoptosis determination using a fluorescence microscopic assay following staining of the drug-
treated cells with Hoescht 33258. The immunoblotting results indicated that the synergistic killing due to 17-DMAG
and TNF treatments may be related to the decreases in IKKβ levels in the presence of 17-DMAG.
Conclusions: The results suggest that combination of 17-DMAG and TNF treatments might be useful for treating
malignancies upon further study in the further.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/2041198513886824
Keywords: 17-DMAG, IKKβ, TNF, NF-κB PathwayIntroduction
Heat shock proteins (Hsps) are a group of chaperones
that are important in maintaining stability and function
of their client proteins. Heat shock protein 90 (Hsp90)
regulates stability, degradation, translation, and function
of its client proteins, via an ATP-regulated mechanism
[1]. Unlike other Hsps, only approximately 200 cellular
proteins are determined to be clients of Hsp90 [2-4].
Hsp90 inhibitors, such as 17-DMAG, are a group of
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reproduction in any medium, provided the orthe Hsp90 dimers [5,6]. By competing with ATP, 17-
DMAG can inhibit the protein chaperoning activity of
Hsp90, resulting in misfolding of cellular client proteins
such as the tyrosine kinase v-Src, the serine/threonine
kinase Raf, mutant p53 proteins, the glucocorticoid
receptor, and the androgen receptor HER2, resulting in
protein destabilization and degradation, usually medi-
ated by the proteasomal pathway [7]. A number of
Hsp90 clients are involved in tumor developments [7].
In addition, the binding affinity of Hsp90 inhibitors to
the ATP-binding pocket of Hsp90 are 10-flod higher in
tumor cells than in normal cells [8]. Therefore, Hsp90
inhibitors are promising therapeutic reagent for treating
malignant cells.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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in various cellular processes such as cell proliferation,
survival, differentiation, and apoptosis [9]. Since TNF
can induce apoptosis of cells, it may be a potential thera-
peutic agent to treat cells. However, TNF induces mul-
tiple pathways including cell proliferation and survival
processes that may facilitate tumor development [10].
Therefore, combination of TNF and another agent will
be a promising method of treating malignant cells, if this
agent can down-regulate the cell proliferation property
of TNF. Therefore, novel reagents are necessary to in-
hibit TNF-induced survival signals, possibly by resulting
in a synergistic effect on malignant cells.
When TNF binds to the TNF receptors, a group of
signaling pathways were activated. For example, the
caspase cascade can be activated through the Fas-
associated death domain protein, which leads to apop-
tosis [10]. However, activation of the NF-κB pathway
through the receptor-interaction protein upon binding
of TNF facilitates cell survival and proliferation [11-13],
which will decrease the anti-tumor apoptotic properties
of TNF. Therefore, the balance of TNF-induced survival
and death signaling is essential for the fates of cells in
the presence of TNF.
During TNF-induced signaling, IκB kinases (IKKs),
including IKKα, IKKβ, and IKKγ, are recruited to the
signaling complex. The activated IKKβ then phosphory-
lates the NF-κB-bound IκBs, which retain NF-κB in the
cytoplasm, at their regulatory region to trigger their
degradation. This process releases NF-κB to allow its
translocation into the nucleus and activation of its target
genes [14,15], with many of them possessing anti-
apoptotic properties [16-18]. Since IKKβ has been iden-
tified as an Hsp90 client protein [19,20], we hypothesize
that combined treatments with 17-DMAG and TNF
may lead to a promising anti-tumor effects if 17-DMAG
can decrease the survival signaling properties of TNF.
Since TNF and 17-DMAG may be useful for treating
some types of malignancies. In this study, we have deter-
mined the effects of 17-DMAG and TNF treatments on
multiple cell lines. It is found that the combined treat-
ments result in synergistic killing of cells. It is also
indicated that such a synergistic killing may be related
to the decreases in IKKβ levels in the presence of
17-DMAG. Our results suggest that combination of
17-DMAG and TNF might be useful for treating malig-
nancies upon further study in the further.
Materials and methods
Cell lines and reagents
The small cell lung cancer (SCLC) cell line (MS-1), the
adenocarcinoma cell line (A549), the squamous-cell
carcinoma cell line (LK-2), and the normal human bron-
chial epithelium cell line (NuLi-1) were provided byShanghai Cell Biology Institute (China). These lung can-
cer cell lines were maintained in RPMI-1640 medium
(Sigma-Aldrich Co. Ltd, Irvine, CA) supplemented with
10% fetal bovine serum (FBS), 1% L-glutamine, and 1%
penicillin/streptomycin at 37°C with 5% CO2 and 100%
humidity. 17-DMAG (InvivoGen, San Diego, CA) and
TNF-α (TNF) were dissolved in DMSO. Recombinant
Human TNF was purchased from Promega.
Cell treatments and the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrozolium bromide (MTT) assay
Briefly, cells at a density of 1 × 105 cells/well were
seeded into 6-well plates in RPMI-1640 supplemented
with 10% calf serum and were cultured for 24 h. The
cells were then treated with vehicle control (DMSO,
0.016%, v/v), TNF-α (10 ng/ml), 17-DMAG (0.05 μM),
or TNF-α (10 ng/ml) plus 17-DMAG (0.05 μM). At the
end of each experiment, cells were incubated with 0.5
mg/ml MTT for 4 h according to the protocol of manu-
facturer. Viability of treated cells was expressed relative
to control cells (relative viability).
Apoptosis assay
Cells at a density of 1 × 105 cells/well were cultured in
six-well plates in RPMI-1640 supplemented with 10%
calf serum for 24 h, followed by addition of DMSO
(0.016%, v/v), TNF (10 ng/ml), 17-DMAG (0.05 μM), or
TNF (10 ng/ml) plus 17-DMAG (0.05 μM). After 48 h,
cells were pelleted by centrifugation, washed once with
PBS, fixed by incubation in 4% paraformaldehyde for 30
min at room temperature, and then washed again with
PBS to remove the fixative. The fixed cells were
resuspended in PBS that contained Hoescht 33258
(5 μg/ml), followed by an incubation at room
temperature for 15 min in the dark. Aliquots of cells
were placed on glass slides and examined for cells with
apoptotic morphology (nuclear condensation and chro-
matin fragmentation) via fluorescence microscopy. To
quantify the apoptosis, 300 nuclei from random micro-
scopic fields were analyzed. Data are presented as the
mean percentages of apoptotic cells.
Immunoblotting assays
Cells at a density of 1 × 105 cells/well were cultured in
six-well plates in RPMI-1640 supplemented with 10%
calf serum for 24 h, followed by addition of DMSO
(0.016%, v/v), TNF (10 ng/ml), 17-DMAG (0.05 μM), or
TNF (10 ng/ml) plus 17-DMAG (0.05 μM). After 48 h,
cells were pelleted by centrifugation, washed twice with
PBS. Total proteins were harvested from cells, separated
on 10% SDS/PAGE gels, and then subjected to immuno-
blot analyses. The primary antibodies against IKKβ
(about 90 kDa) and β-actin were purchased from Santa
Cruz, USA (anti- IKKβ, cat# sc-8014, 1:200; anti-
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used in this study were goat anti-mouse IgG-HRP (Cat#
sc-2005, 1:10,000, Santa Cruz, USA). Bound antibodies
were detected using the ECL system (Pierce Biotechnol-
ogy). The immunoblot experiments were repeated at
least 3 times. The mean normalized optical density (OD)
of HDAC protein bands relative to the OD of β-actin
band from the same individual was calculated.
Luciferase assays
NuLi-1 cells, MS-1 cells, A549 cells, and LK-2 cells were
plated onto 24-well plates and incubated for 20 h at
37°C in 5% CO2. The control pGL3 vector DNA (0.2 μg)
(purchased from Clontech Co.) or similar amounts of
Luciferase-NF-κB reporter vectors (Clontech Co., USA),
was cotransfected into cells with the pRL-SV40 vector
using the effectene transfection reagent (Qiagen, USA)
for 20 h. Cells were then treated with DMSO (0.016%,
v/v), TNF (10 ng/ml), 17-DMAG (0.05 μM), or TNF (10
ng/ml) plus 17-DMAG (0.05 μM) for 24 h. Luciferase
activity was measured using the Dual-Luciferase Re-
porter Assay System (Promega, USA) according to the
manufacturer's protocol. The transcriptional activity of
NF-κB in the cells transfected with the Luciferase-NF-κBFigure 1 Cell treatments with DMSO, TNF-α, 17-DMAG, or TNF-α and
(NuLi-1) and three lung cancer cell lines (MS-1, A549, and LK-2) were treate
μM), or both. Cell counts in each condition were determined by trypan blu
(C) A549 cells; (D) LK-2 cells. Cell viability was measured using 3-(4,5-dimeth
immediately before (day 0) and after 1, 2, or 3 days of incubation with the
not significant, when P > 0.05 vs. control (DMSO) cell viability of each treat
corresponding control.reporter vectors were calculated as folds of those in the
relative cells transfected with the empty vector.
Statistical analyses
The experimental data are expressed as mean ± SD.
Statistical software (SPSS10.0) was used for independent
sample t tests, followed by one-way variance analysis. In all
analyses, P < 0.05 was considered statistically significant.
Results
TNF-α enhances the toxic effects on tumor cells of
17-DMAG
A normal human bronchial epithelium cell line (NuLi-1)
and three lung cancer cell lines (MS-1, A549, and LK-2)
were treated with TNF, 17-DMAG, or both of them to-
gether for 24 hour or 48 hours. The treatment with
DMSO served as a drug vehicle control. The cells were
analyzed for differences in cell killing upon various treat-
ments via number counting of living cells in the pres-
ence or absence of the above compounds.
Results showed that the treatments with the drug
vehicle control (DMSO) did not significantly affect cell
viability of all of these four types of cells, including the
normal human bronchial epithelium cell line (NuLi-1,17-DMAG together. The normal human bronchial epithelium cell line
d with either vehicle control (DMSO), TNF-α (10 ng/ml), 17-DMAG (0.05
e exclusion at the time points indicated. (A) NuLi-1 cells; (B) MS-1 cells;
ylthiazol-2-yl)-2,5-diphenyltetrozolium bromide (MTT) assay
drugs. Values are means ± SD for three experiments. It is considered
ment. *, it is considered as a significant difference, when P < 0.05 vs.
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(Figure 1B), A549 (Figure 1C), and LK-2 (Figure 1D).
Treatments with TNF-α had slight effects, if any, on cell
viability of all of these four types of cells (Figure 1A-D).
Treatments with 17-DMAG decreased viabilities of the
three lung cancer cell lines MS-1 (Figure 1B), A549
(Figure 1C), and LK-2 (Figure 1D) by approximately 40%
at day 2 and up to 60% at day 3, but no obvious de-
creases for the normal human bronchial epithelium cell
line (NuLi-1, Figure 1A). When treated with TNF-α and
17-DMAG together, the viabilities of the three lung can-
cer cell lines MS-1 (Figure 1B), A549 (Figure 1C), and
LK-2 (Figure 1D) were reduced by more than 80% at day
2 and by 90% at day 3. Combined treatments with TNF-
α and 17-DMAG had not significantly decreased the via-
bility of the normal cells (NuLi-1, Figure 1A), suggesting
that such dosages of TNF-α and 17-DMAG are not toxic
to normal cells. The above results suggest that TNF-α
enhances the toxic effects on tumor cells of 17-DMAG.TNF-α enhances the apoptosis induced by 17-DMAG
Since TNF-α enhances the toxic effects on tumor cells
of 17-DMAG, it was determined that the effects of the
drugs on apoptosis in all of these 4 types of cells. The
cells were treated with either vehicle control (DMSO),
TNF-α (10 ng/ml), 17-DMAG (0.05 μM), or both of
TNF-α (10 ng/ml) and 17-DMAG (0.05 μM). To quan-
tify the apoptotic incidence, we used a fluorescence
microscopic assay following staining of the drug-treated
cells with Hoescht 33258.
As shown in Figure 2, treatment with DMSO or TNF-
α resulted in only slightly increased effects on apoptosis
of all of these four types of cells. 17-DMAG caused
apoptosis of MS-1, A549, and LK-2 cells with the inci-
dences between 50-60%, although it did not alter theFigure 2 Detection of phenotype-dependent apoptosis induced by tr
The normal human bronchial epithelium cell line (NuLi-1) and three lung c
control (DMSO), TNF-α (10 ng/ml), 17-DMAG (0.05 μM), or both of TNF-α (1
33258-stained cells were examined for apoptotic characteristics (nuclear m
microscope. Apoptotic incidence was calculated. Data were expressed as mapoptotic incidence of the normal NuLi-1 cells signifi-
cantly when compared with the DMSO treatment. It is
worthy to note that the presence of TNF-α increased the
17-DAMG induced apoptosis, with the incidences up to
90% in comparison with the treatments with 17-DMAG
alone. These results indicated that TNF significantly
elevated the apoptosis induced by 17-DAMG, although
it alone did not result in a significant induction of
apoptosis.17-DMAG treatments lead to degradation of IKKβ
IKKβ expression is reported to be reduced by Hsp90 in-
hibitors in some cell types. To determine if 17-DMAG
inhibit the expression of IKKβ in NuLi-1, MS-1, A549,
and LK-2 cells, the cells were treated with either vehicle
control (DMSO), TNF-α (10 ng/ml), 17-DMAG (0.05
μM), or both of TNF-α (10 ng/ml) and 17-DMAG (0.05
μM). The total proteins were extracted and the expres-
sion levels of IKKβ were determined by using immuno-
blot analysis, with the cellular β-actin protein serving as
a loading control. The mean normalized OD of IKKβ
protein bands relative to the OD of β-actin band from
the same condition was all calculated and subjected to
statistical analyses.
Representative blots were shown in Figure 3. As
shown in Figure 3, treatment with DMSO or TNF-α did
not detectably affect IKKβ expression in all of these four
types of cells. 17-DMAG, in the absence or presence of
TNF-α, did not result in decreased expression of IKKβ
in the normal NuLi-1 cells. However, the treatments
with 17-DAMG decreased expression of IKKβ by up to
50%, 80%, and 90% in MS-1, A549, and LK-2 cells cells,
respectively, according to the calculated OD values of
the IKKβ bands relative to the β-actin bands. These re-
sults indicated that 17-DMAG significantly decreasedeatments with DMSO, TNF-α, 17-DMAG, or TNF-α plus 17-DMAG.
ancer cell lines (MS-1, A549, and LK-2) were treated with either vehicle
0 ng/ml) and 17-DMAG. Cells were harvested 48 h later. Hoechst
argination and chromatin condensation) using a fluorescence
eans ± SD for three independent experiments.
Figure 3 17-DMAG decreases expression of IKKβ. Cells were treated with DMSO, TNF-α (10 ng/ml), 17-DMAG (0.05 μM), or both of TNF-α
(10 ng/ml) and 17-DMAG for 40 hours. Whole-cell extracts were prepared and immunoblot analysis was performed to analyze the expression of
IKKβ, β-actin. The cellular β-actin served as a loading control. (A) NuLi-1 cells; (B) MS-1 cells; (C) A549 cells; (D) LK-2 cells.
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effect of 17-DMAG.
17-DMAG down-regulates the NF-κB transcriptional
activity induced by TNF treatment
Next, we performed a luciferase reporter gene assay to
determine whether TNF-α induces transcriptional activ-
ity of NF-κB and, if so, whether 17-DMAG affects the
induction of NF-κB transcriptional activity by TNF-α.
NuLi-1 cells, MS-1 cells, A549 cells, and LK-2 cells wereFigure 4 Luciferase reporter gene assay. NuLi-1 cells, MS-1 cells, A549 c
20 h at 37°C in 5% CO2. The control pGL3 vector DNA (0.2 μg) or similar am
cells with the pRL-SV40 vector using the effectene transfection reagent. Ce
17-DMAG (0.05 μM), or TNF (10 ng/ml) plus 17-DMAG (0.05 μM) for 24 h. L
repeated thrice with similar results. *, it is considered as a significant differetransfected with a control pGL3 vector DNA or similar
amounts of Luciferase-NF-κB reporter vectors together
with the pRL-SV40 vector for 20 h.
As shown in Figure 4, treatments with TNF-α resulted
in 3-fold higher luciferase activities in NuLi-1 cells and
about 6-flod higher luciferase activities in MS-1 cells,
A549 cells, and LK-2 cells, when compared with the
DMSO conditions. Treatments with 17-DMAG did not
lead to detectable alteration of the luciferase activities in
NuLi-1 cells, but reduced the luciferase activities in MS-ells, and LK-2 cells were plated onto 24-well plates and incubated for
ounts of Luciferase-NF-κB reporter vectors, was cotransfected into
lls were then treated with DMSO (0.016%, v/v), TNF (10 ng/ml),
uciferase activity was measured in cell lysates. Each experiment was
nce, when P < 0.05 vs. corresponding control.
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parison with the DMSO conditions. Upon treatments
with TNF-α and 17-DMAG together, the luciferase activ-
ities in NuLi-1 cells were not significantly changed, but
the activities in MS-1 cells, A549 cells, and LK-2 cells were
reduced by about 70-80%, in comparison with the DMSO
conditions. These results indicated that 17-DMAG down-
regulates the NF-κB transcriptional activity induced by
TNF treatment.
Discussion
Since many Hsp90 clients are important for disease de-
velopment, 17-DMAG is extensively studied for possible
treatments of various diseases [21-25]. In this study, we
have determined the effects of 17-DMAG and TNF
treatments on multiple cell lines. It is found that the
combined treatments result in synergistic killing of ma-
lignant cells. It is also indicated that such a synergistic
killing may be related to the decreases in IKKβ levels in
the presence of 17-DMAG. Our results suggest that
combination of 17-DMAG and TNF might be useful for
treating malignancies upon further study in the further.
Combined treatments with TNF-α and 17-DMAG had
not significantly decreased the viability of the normal
NuLi-1 cells, but leads to obvious toxicity on malignant
MS-1, A549, and LK-2 cells. This result may be related
to the properties of Hsp90. As one of the most abundant
proteins in the cytoplasm, Hsp90 constitutes approxi-
mately 1-2% of the total proteins [26], although some
Hsp90 may translocate to the nucleus in response to
stress and other environmental stimuli [27-30]. Under
normal conditions of the normal cells, there is an
abundant Hsp90 chaperone reservoir, which can buffer
proteostasis against environmental stress. However,
under extreme environmental conditions, such as con-
ditions in malignant cells, the chaperone reservoir is
rapidly exhausted. Therefore, effects of 17-DMAG may
be increased correspondingly. In the other words,
function of Hsp90 inhibitors can then affect the rela-
tionship between genotype and phenotype, and thus
influencing human health, disease and evolutionary
processes. This reason also explains why 17-DMAG
did not affect IKKβ expression in normal cell.
Hsp90 is composed of a highly conserved amino-
terminal domain, a middle domain, followed by a
carboxy-terminal domain [31]. Hsp90 binds ATP in its
amino-terminal domain, hydrolyzing it upon inter-
action with clients and co-chaperoning molecules.
Structurally unrelated inhibitors of Hsp90, such as 17-
DMAG, replace ATP and specifically destroy Hsp90
function [32]. The strong conservation of the ATP-
binding pocket allows 17-DMAG to serve as extremely
useful and specific tools for affecting HSP90 function.
This may explain why TNF did not enhance the effectof 17-DMAG on IKKβ expression, while they exert a
combined effect on viability of malignant MS-1, A549,
and LK-2 cells, possibly by playing roles in different
cellular signaling pathways or processes.
When cells are treated with TNF, NF-κB is activated
through RIP-mediated activation of IκB kinase (IKK)
and then released, allowing for its translocation into the
nucleus and activation of its target genes [14]. Many cel-
lular targets of NF-κB, such as Bcl-xL, cIAP-1, A20,
cIAP-2, and XIAP, have anti-apoptotic functions [16-18].
Therefore, many kinds of tumor cells are resistant or tol-
erant to TNF-induced apoptosis, although TNF may lead
to apoptosis via the FADD-caspase pathway and the
TRAF2-JNKK2 pathway. The NF-κB activity is consid-
ered as a major factor of TNF resistance in cancer cells
[33]. Our results clearly show that inhibition of the
NF-κB pathway by 17-DMAG significantly sensitizes the
TNF-treated cells to induced cell death, supporting the
combined effects of 17-DMAG and TNF on cells
through a mechanism related to the NF-κB pathway. In
addition to the small-molecule compounds such as
17-DMAG, the siRNA strategies are often used to treat
tumor cells. It is found that targeting the fascin pathway
by using a specific siRNA might be a novel therapeutic
strategy for curing the esophageal squamous cell carcin-
oma [34]. Compounds can be also used for study of gene
expression. It has been reported that gene expression
profile test is useful to resolve the lung squamous
cancers and other cancers such as the head and neck
squamous carcinoma [35].
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